Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Refractory SLE (DARALUP)
NCT04810754Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of daratumumab in systemic lupus erythematosus (SLE), sponsored by Charité – Universitätsmedizin Berlin. Status: unknown.
02
Drugs
daratumumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04810754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810754.